Waystar Considers Sale Amidst Falling Market Value, Sources Reveal

Waystar, a prominent healthcare software provider, is reportedly considering a sale, according to sources familiar with the situation. The company, which helps hospitals and doctors manage payments through its technology, has enlisted investment bank Evercore to explore strategic options. This move comes just two years after Waystar's public listing in New York.

Potential Sale and Market Context

Sources indicate that the discussions are in preliminary stages and may not necessarily result in a sale. However, the exploration of strategic alternatives reflects Waystar's response to a significant decline in its market value. The company's share price has dropped by 24% this year, reducing its market capitalization to approximately $4.8 billion. This decline is part of a broader downturn affecting the software sector.

The company had initially positioned itself as a technology-focused entity, aiming to capitalize on the higher valuations typically associated with tech firms. This strategy initially paid off, with shares climbing from $20 to a peak of $45 in 2025. However, investor concerns over potential disruptions from advancements in artificial intelligence have since exerted pressure on the stock, according to a July report by Morgan Stanley analysts.

Background and Ownership

Waystar was established in 2017 following the merger of Zirmed and Navicure, two healthcare revenue management companies. The company went public in 2024, backed by major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB holding 10%, and BlackRock Institutional Trust Company with 8%, as per LSEG data.

Despite the current exploration of a sale, EQT and other major stakeholders have declined to comment on the matter. Similarly, Evercore has not provided a response to inquiries about their advisory role in the process.

Investor Sentiment and Future Prospects

The decision to consider a sale could serve as a test of investor interest in software companies amidst current market conditions. The outcome of this process may signal broader trends in the valuation and appetite for healthcare technology firms. Meanwhile, Waystar continues to focus on its core offering of automating and managing administrative healthcare tasks, distinguishing itself from traditional service-oriented healthcare businesses.